Related Experiment Video

Updated: Apr 27, 2026

In Vitro Assays to Evaluate the Migration, Invasion, and Proliferation of Immortalized Human First-trimester Trophoblast Cell Lines
09:57

In Vitro Assays to Evaluate the Migration, Invasion, and Proliferation of Immortalized Human First-trimester Trophoblast Cell Lines

Published on: March 5, 2019

9.8K

TRAF6 inhibition rescues dexamethasone-induced muscle atrophy

Hualin Sun1, Yanpei Gong2, Jiaying Qiu3

  • 1Jiangsu Key Laboratory of Neuroregeneration, Co-Innovation Center of Neuroregeneration, Nantong University, Nantong 226001, Jiangsu, China. sunhl@ntu.edu.cn.

International Journal of Molecular Sciences
|June 24, 2014
PubMed

Insights

Tumor necrosis factor receptor-associated factor 6 (TRAF6) is a key regulator in dexamethasone-induced muscle atrophy. Reducing TRAF6 expression can prevent muscle loss by downregulating MAFBx and MuRF1.

Area of Science:

  • Biochemistry
  • Molecular Biology
  • Physiology

Background:

  • Tumor necrosis factor receptor-associated factor 6 (TRAF6) is an E3 ubiquitin ligase crucial for signaling pathways.
  • TRAF6 has emerged as a significant regulator in skeletal muscle atrophy.
  • The specific role of TRAF6 in glucocorticoid-induced muscle atrophy requires further investigation.

Purpose of the Study:

  • To elucidate the role of TRAF6 in dexamethasone-induced skeletal muscle atrophy.
  • To investigate the relationship between TRAF6, MAFBx, and MuRF1 in muscle atrophy.

Main Methods:

  • Utilized mouse C2C12 myotubes and mouse tibialis anterior (TA) muscle models.
  • Induced muscle atrophy using dexamethasone.
  • Employed TRAF6-siRNA to knockdown TRAF6 expression in vitro and in vivo.

Main Results:

  • TRAF6, MAFBx, and MuRF1 expression were upregulated in dexamethasone-induced muscle atrophy.
  • TRAF6 knockdown significantly attenuated dexamethasone-induced muscle atrophy.
  • TRAF6 inhibition decreased the expression of MAFBx and MuRF1.

Conclusions:

  • TRAF6 plays a critical role in dexamethasone-induced skeletal muscle atrophy.
  • Decreasing TRAF6 expression offers a potential therapeutic strategy for muscle atrophy.
  • TRAF6 influences muscle atrophy, at least partly, through the regulation of MAFBx and MuRF1.

More Related Videos

Performing Human Skeletal Muscle Xenografts in Immunodeficient Mice07:48

Performing Human Skeletal Muscle Xenografts in Immunodeficient Mice

Published on: September 16, 2019

9.6K
Preclinical Drug Testing in Scalable 3D Engineered Muscle Tissues08:07

Preclinical Drug Testing in Scalable 3D Engineered Muscle Tissues

Published on: April 7, 2023

5.7K

Related Concept Videos

Directly Acting Muscle Relaxants: Dantrolene and Botulinum Toxin01:26

Directly Acting Muscle Relaxants: Dantrolene and Botulinum Toxin

Directly acting muscle relaxants like dantrolene and botulinum toxin (BoNT) have distinct mechanisms and applications. Dantrolene, a hydantoin derivative, acts on the ryanodine receptor (RYR1) in skeletal muscle cells. RYR1 are calcium channels present at the sarcoplasmic reticulum membrane. In response to excitation, they release calcium ions from the sarcoplasmic reticulum to the cytosol. Calcium promotes actin-myosin-mediated contraction of muscles.
The binding of dantrolene to the RYR1...
2.2K
Skeletal Muscle Relaxants: Therapeutic Uses01:31

Skeletal Muscle Relaxants: Therapeutic Uses

Skeletal muscle relaxants are used to relax muscle tone and alleviate painful muscle contractions. However, the choice of skeletal muscle relaxants depends on the duration of the surgical procedure in order to minimize potential side effects. Skeletal muscle relaxants like neuromuscular blocking agents [NMBAs] are commonly employed as adjuvants alongside general anesthetics in clinical settings. NMBAs are also used to maintain controlled ventilation during surgery of the larynx or pharynx...
1.2K
Skeletal Muscle Relaxants: Adverse Effects01:21

Skeletal Muscle Relaxants: Adverse Effects

Skeletal muscle relaxants are widely used for muscle paralysis and relieving pain following any muscle injury or stiffness. However, depending on the drug type, they can have adverse effects that range from mild to severe. Usually, nondepolarizing neuromuscular blockers have minimal side effects. For example, drugs like d-tubocurarine, cisatracurium, and rocuronium cause hypotension, whereas drugs like baclofen, when stopped abruptly, can lead to the recurrence of spastic conditions.
Unlike...
1.2K